Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00273520 | TELICAST : Telithromycin in Acute Exacerbations of Asthma | PHASE3 | COMPLETED | - | — | — | Jan 1, 2003 | May 1, 2004 | Sep 15, 2009 | - | — |
| Name | Type | Description |
|---|---|---|
| Telithromycin | DRUG | - |
Inclusion criteria Patients meeting all of the following criteria will be considered for enrollment in the study: * A documented history of asthma for \>6 months * Presenting within 24 hours of initial medical care in an urgent care clinic, emergency room, or in-patient hospital setting. To qualif...